Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Artivion, Inc. (NYSE:AORT)

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Artivion shares on July 16, according to a congressional disclosure. He also reported several other recent stock purchases and sales.
• Artivion reported quarterly EPS of $0.13 and revenue of $125.76 million, exceeding the consensus revenue estimate of $119.99 million. The stock opened at $25.59, with a market capitalization of approximately $1.25 billion.
• Analyst sentiment remains broadly positive, with seven Buy ratings and one Sell rating and a consensus price target of $44.83. However, company insiders sold 122,981 shares worth about $3.18 million over the past 90 days.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Artivion, Inc. (NYSE:AORT). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Artivion stock on July 16th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Mesabi Trust NYSE: MSB on 7/31/2026.
• Purchased $1,001 - $15,000 in shares of Praxis Precision Medicines NASDAQ: PRAX on 7/30/2026.
• Purchased $15,001 - $50,000 in shares of Alkermes NASDAQ: ALKS on 7/30/2026.
• Sold $15,001 - $50,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 7/30/2026.
• Sold $100,001 - $250,000 in shares of Alibaba Group NYSE: BABA on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of SailPoint NASDAQ: SAIL on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of Glacier Bancorp NYSE: GBCI on 7/21/2026.
• Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 7/21/2026.

Artivion Stock Performance

Artivion stock opened at $25.59 on Tuesday. The company's 50-day moving average price is $26.15 and its 200-day moving average price is $29.08. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.25 billion, a PE ratio of -365.52 and a beta of 1.25. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The firm had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. On average, equities research analysts forecast that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Artivion

Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in Artivion during the 3rd quarter valued at about $27,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock worth $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company's stock worth $43,000 after purchasing an additional 563 shares during the period. Smartleaf Asset Management LLC boosted its position in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after buying an additional 538 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in Artivion in the 4th quarter worth approximately $79,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Artivion from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Weiss Ratings downgraded Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Canaccord Genuity Group raised their target price on shares of Artivion from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Tuesday, August 18th. Finally, Stifel Nicolaus set a $45.00 price target on Artivion in a research report on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Artivion has an average rating of "Moderate Buy" and a consensus price target of $44.83.

Insiders Place Their Bets

In related news, SVP Andrew M. Green sold 44,001 shares of the business's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares in the company, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO James P. Mackin sold 70,000 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total value of $2,026,500.00. Following the sale, the chief executive officer directly owned 877,275 shares in the company, valued at $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 122,981 shares of company stock valued at $3,181,531. 6.30% of the stock is owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.